Market News · SMCI

The Cloud Over SMCI Is Finally Lifting

The internal investigation ended far better than shareholders feared — but this story is not completely over.

Super Micro Computer has spent months with a federal investigation hanging over its head. Now SMCI shareholders finally have a reason to breathe a little easier.

An independent board-led investigation found no evidence that the company's current senior management knew about or participated in the alleged diversion of restricted AI servers to China. Investigators also found no evidence that SMCI knowingly sold restricted products directly to prohibited customers or locations.

Just as important, the investigation found no reason to question the company's financial statements because of those sales.

That is a big deal — but let's not get carried away. This was not some minor paperwork problem. Federal prosecutors accused three former SMCI associates of using false documents, overseas intermediaries and hidden shipping destinations to move advanced AI servers into China. They allegedly went so far as to stage dummy servers to fool inspectors.

SMCI itself was not charged. The three individuals are no longer associated with the company, and several other employees were terminated for failing to follow company policies. SMCI is also strengthening its export-compliance program.

The company's internal investigation is finished, but the government's investigation is still ongoing. So the cloud has lifted considerably, but it hasn't completely disappeared.

At least investors can begin looking at the actual business again. Management expects fiscal 2027 revenue of at least $65 billion, driven by demand for AI servers and liquid-cooled data-center systems. That is a huge number — but huge sales only matter if SMCI can turn them into strong profits.

Wall Street is still being careful. The stock has a consensus "Hold" rating and an average price target of approximately $41, compared with a recent price near $37. Analysts are relieved, but they aren't exactly throwing a parade.

Sources: Super Micro Computer investigation announcement; U.S. Department of Justice; Barchart analyst ratings.

Not Subscribed Yet?

Sign up for the newsletter here

Market Commentary · MRNA

Moderna's Breakthrough Was Real — So Was the Overreaction

Promising science triggered a 177% celebration before Moderna had an approved product to sell.

Moderna delivered legitimate good news. Wall Street responded as if the company had already conquered cancer.

Shares exploded 177% Wednesday after Moderna and Merck announced positive Phase 3 results for their personalized melanoma treatment. The study met its major goals, giving investors the breakthrough they had been waiting for — and adding roughly $45 billion to Moderna's market value in a single session.

That was not a normal rally. It was an emotional stampede.

Everyone would deeply appreciate a genuine cure for cancer. Hopefully, this treatment represents an important step in that direction. But the announcement was not a universal cure, an FDA approval or a product ready for patients. Investors temporarily traded it as though all three had happened.

The excitement carried Moderna from $62.96 to $174.40 in one day, pricing years of possible approvals, production and sales into the stock almost overnight.

Then came Thursday's reality check. Traders locked in profits, and Moderna fell $41.08, or 23.56%, to $133.32. At one point, shares touched $128.61. The medical news had not changed. What changed was investors' willingness to keep paying a price inflated by one of Wall Street's most dramatic one-day rallies.

The selloff did not erase the breakthrough. It exposed the difference between a promising trial result and a reasonable stock valuation. Wednesday's buyers paid upfront for nearly everything that might go right tomorrow.

Sources: Moderna & Merck Phase 3 announcement; Nasdaq market data. Data as of Aug. 20, 2026 close.

Cybersecurity Watch · CRWD

CrowdStrike Earnings Just Got More Interesting

A longtime technology leader is walking away just days before earnings. That deserves attention — but not panic.

CrowdStrike shares slipped after Global CTO Elia Zaitsev announced he was leaving after 13 years with the company. He is moving on to co-found Cognition, a venture firm looking to raise $170 million to invest in AI and cybersecurity companies.

I don't love seeing a longtime technology executive walk away — especially less than a week before earnings. But I'm not ready to turn one departure into a disaster, either. CrowdStrike remains a major cybersecurity company and was just named the strongest overall leader in Frost & Sullivan's 2026 cloud workload protection report.

CrowdStrike reports after the close on August 26. That is when we should get a better feel for whether investors have something to worry about or whether the market simply overreacted to the headline.

Sources: CrowdStrike public statements; Frost & Sullivan 2026 cloud workload protection report. For informational purposes only. Not investment advice.

Free Community

Join our Discord with over 1,000 like-minded traders who believe that math makes money when it comes to trading

Trade ideas, screenshots, daily banter. Zero cost.